Browse Category: Cancer Research

Exploring The Contribution of Clay Siegall To Cancer Research

 

Research aimed at delivering new ways of treating cancer has been on for many years. In the past decade, many companies in the pharmaceutical industry have pumped more funds and energy into cancer research and their objective has been to come up with a reliable technology that can make cancer treatment easier and more successful. Among these companies is Seattle Genetics, a company that has proved to offer modern solutions to the development of the industry. Seattle Genetics has been funding and pursuing research to unveil new treatment methods for cancer.

Under the leadership of Clay Siegall, who also co-founded the company, Seattle Genetics has managed to release different drug pipelines like ADCETRIS, which has recorded a lot of success across the world. Most importantly, Seattle Genetics developed the ADC Technology, whose focus is discriminating cells while treating cancer to ensure only infected cells are eliminated.

The traditional radiation method of killing cancer cells does not effectively achieve this as it also kills cells that are healthy, thereby weakening the patient further. ADC will ensure patients are not exposed to the risk of losing healthy cells while receiving treatment. Seattle Genetics has also been able to invite other companies to support the development of superior drug pipelines and technologies that could help them to achieve a milestone in cancer treatment.

About Clay Siegall

Clay B. Siegall, the founder, CEO and President of Seattle Genetics, is a clinical scientist, whose passion in medicine has motivated him to invest more into cancer research and the development of treatment options that are geared towards enhancing treatment practices. His company has been sponsoring research in this field and over the past 10 years, they unveiled several products, among them the ADC Technology, which allows for better ways of treating cancer.

He also expressed satisfaction in the introduction of ADCETRIS to be part of the drug pipelines the company produces to support cancer treatment. Clay Siegall acquired a bachelor’s degree in Zoology from the Maryland University and a PhD in Genetics from Washington University. Prior to launching Seattle Genetics, he served at the National Institute of Health.